Delving into the Latest Updates on Urokinase biosimilar(Sedico BV) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Enzyme

Synonyms

Angikinase, Urokinase biosimilar

Target

PLG

Mechanism

PLG stimulants(Plasminogen stimulants)

Therapeutic Areas

Cardiovascular DiseasesRespiratory Diseases

Active Indication

Myocardial InfarctionPulmonary EmbolismThromboembolism

Inactive Indication-

Originator Organization

Sedico BV

Active Organization

Sedico BV

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

EG (01 Jan 2014),

Myocardial InfarctionPulmonary EmbolismThromboembolism

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 140418028

The sequence is quoted from: *****

Sequence Code 565458424

The sequence is quoted from: *****

BACKGROUNDBiosimilar drugs offer an opportunity for all global healthcare systems because they provide significant cost savings while ensuring equal efficacy and safety in the treatment of chronic diseases. These savings can be allocated to support ongoing innovation.METHODSAn analysis of the usage of major biosimilar drugs across various therapeutic areas has been conducted within an Italian healthcare company serving a population of over one million. Data on consumption, expenditure, and the number of treated patients has been extracted from the company's databases. Finally, a comparison with the year 2021 has been performed to determine if biosimilar drug usage increased in 2022.RESULTSIn 2022, the data reveals that a substantial portion of the analysed active ingredients are being used as biosimilar drugs, except in a few residual cases. However, among the most consumed drugs, resistance still exists in the case of Adalimumab and Etanercept, for which expenditure on originator drugs exceeds 2 million euros.CONCLUSIONThe 2022-2021 comparison highlights the increasing use of biosimilar drugs. This data is encouraging and suggests that in the coming months, we may achieve total utilization, which would be to the benefit of the National Health System (NHS) and the citizens who can rely on an efficient and sustainable healthcare policy that is continually improving.

100 Deals associated with Urokinase biosimilar(Sedico BV)

Login to view more data